November 20, 2026 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · DOI: 10.1200/JCO-26-00854

Alectinib as Neoadjuvant Treatment in Potentially Resectable Stage III Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: ALNEO Phase II Trial (GOIRC-01-2020-ML42316).

Listen to this summary

The ALNEO phase II trial asked whether 8 weeks of neoadjuvant alectinib followed by surgery and adjuvant alectinib is active and feasible in treatment-naïve, potentially resectable stage III ALK-positive NSCLC. In 33 patients, the major pathologic response rate was 42% (primary endpoint, 95% CI 26-61%), with 12% achieving pathologic complete response and 85% proceeding to surgery, 86% of whom had R0 resection. Grade ≥3 adverse events occurred in 9% during neoadjuvant treatment and 27% during adjuvant therapy, supporting perioperative alectinib as a feasible and active strategy, though median survival endpoints were not yet reached.

Alessandro Leonetti, Luca Boni, Letizia Gnetti, Simona D'Agnelli, Diego Luigi Cortinovis, Giulia Pasello, Francesco Gelsomino, Francesca Mazzoni, Alessandra Bearz, Giulio Metro, Fabiana Letizia Cecere, Francesco Passiglia, Lorenzo Belluomini, Angelo Delmonte, Serena Ricciardi, Emilio Bria, Federica Bertolini, Luca Toschi, Hector Soto Parra, Mirko Treccani, Roberta Minari, Michele Tognetto, Marcello Tiseo

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

More from Journal of clinical oncology : official journal of the American Society of Clinical Oncology

View all →

Nov 20, 2026 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Reach of State-Mandated Insurance Coverage for Fertility Preservation in Patients With Cancer.

Nov 20, 2026 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Effect of a Multidisciplinary Intervention on Fatigue in Lymphoma Survivors With Persistent Fatigue: A Randomized Controlled Trial (the REFUEL trial).

Nov 17, 2026 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Breast Carcinoma: 5-Year Results of the Multicenter, Randomized, Phase III IRMA Trial.

Nov 13, 2026 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Dasatinib Dose Optimization With Weekend Drug Holiday for Improved Tolerability in Chronic Myeloid Leukemia (DasaHIT): A German Chronic Myeloid Leukemia Alliance Randomized Trial.

Nov 13, 2026 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Early Treatment Failure in Patients With Relapsed/Refractory Multiple Myeloma Receiving Bispecific T-Cell Engagers: Development and Validation of the CHARGE Prognostic Index.

Nov 12, 2026 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Second Cancer Risk in Female Survivors of Hodgkin Lymphoma: A National Cohort Analysis Across Treatment Eras.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play